Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity

v3.22.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Common Stock
Capital in Excess of Par
Retained Earnings (Accumulated Deficit)
Beginning balance (in shares) at Dec. 31, 2018   1,459 22,757    
Beginning balance at Dec. 31, 2018 $ 2,445,208 $ 15 $ 2,276 $ 2,477,278 $ (34,361)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) 67,928       67,928
Shares issued pursuant to employee benefit plans (in shares)     2    
Shares issued pursuant to employee benefit plans 154     154  
Restricted stock (in shares)     79    
Restricted stock 11,630   $ 8 11,622  
Common stock issued for primexx / carrizo acquisitions (in shares)     16,821    
Common stock issued for primexx / carrizo aquisitions 765,373   $ 1,682 763,691  
Common stock warrants reissued in conjunction with Carrizo Acquisition 10,029     10,029 0
Preferred stock dividend (3,997)       (3,997)
Preferred stock redemption (in shares)   (1,459)      
Preferred stock redemption (64,713) $ (15)   (64,698)  
Loss on redemption of preferred stock (8,304)       (8,304)
Ending balance (in shares) at Dec. 31, 2019   0 39,659    
Ending balance at Dec. 31, 2019 3,223,308 $ 0 $ 3,966 3,198,076 21,266
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) (2,533,621)       (2,533,621)
Restricted stock (in shares)     100    
Restricted stock 12,223   $ 10 12,213  
Reverse stock split 0   $ (3,578) 3,578  
Issuance of common stock warrants 9,109     9,109  
Other (17)     (17)  
Loss on redemption of preferred stock 0        
Ending balance (in shares) at Dec. 31, 2020   0 39,759    
Ending balance at Dec. 31, 2020 711,002 $ 0 $ 398 3,222,959 (2,512,355)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net Income (Loss) 365,151       365,151
Restricted stock (in shares)     156    
Restricted stock 10,951   $ 2 10,949  
Warrant exercises (in shares)     6,913    
Warrant exercises 134,817   $ 69 134,748  
Common stock issued for primexx / carrizo acquisitions (in shares)     9,030    
Common stock issued for primexx / carrizo aquisitions 420,700   $ 90 420,610  
Common stock issued for Second Lien Notes Exchange (in shares)     5,513    
Common stock issued for Second Lien Notes Exchange 223,147   $ 55 223,092  
Loss on redemption of preferred stock 0        
Ending balance (in shares) at Dec. 31, 2021   0 61,371    
Ending balance at Dec. 31, 2021 $ 1,865,768 $ 0 $ 614 $ 4,012,358 $ (2,147,204)